A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients treated with neoadjuvant therapy: a multicenter study. (November 2022) - Miglietta, F.; Ragazzi, M.; Fernandes, B.; Griguolo, G.; Massa, D.; Bisagni, A.; Bottosso, M.; Porra, F.; Gaudio, M.; Iannaccone, D.; Fassan, M.; Lo Mele, M.; et al.